CLINICAL TRIALS PROFILE FOR BUSPIRONE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for Buspirone Hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00021528 ↗ | Sequenced Treatment Alternatives to Relieve Depression (STAR*D) | Completed | National Institute of Mental Health (NIMH) | Phase 4 | 2001-07-01 | STAR*D focuses on non-psychotic major depressive disorder in adults who are seen in outpatient settings. The primary purpose of this research study is to determine which treatments work best if the first treatment with medication does not produce an acceptable response. Participants will first receive citalopram, an SSRI medication; if symptoms remain after 8-12 weeks of treatment, up to four other levels of treatment will be offered, including cognitive therapy and other medications. There are no placebo treatments. Some patients may require a combination of two or more treatments to obtain full benefit. Participation could last from 15 to 27 months and involve up to 30 clinic visits. Participants will be interviewed by telephone throughout the study about their symptoms, daily functioning, treatment side effects, use of the health care system, and satisfaction with treatment. There will be a one-year follow up for participants once their depression has been successfully treated |
| NCT00029692 ↗ | Effects of Ginseng and Ginkgo on Drug Disposition in Man | Completed | National Center for Complementary and Integrative Health (NCCIH) | Phase 2 | 2002-03-01 | This study will assess the effects of ginseng and ginkgo on 1) cognitive function, 2) enzymes that process drugs, and 3) enzymes that may help prevent cancer. |
| NCT00053846 ↗ | Buspirone in Reducing Shortness of Breath in Patients With Cancer | Completed | National Cancer Institute (NCI) | Phase 2/Phase 3 | 2002-11-01 | RATIONALE: Buspirone may be effective in reducing dyspnea (shortness of breath) in patients with cancer who are undergoing chemotherapy. PURPOSE: Randomized clinical trial to study the effectiveness of buspirone in reducing shortness of breath in patients who are undergoing chemotherapy for cancer. |
| NCT00053846 ↗ | Buspirone in Reducing Shortness of Breath in Patients With Cancer | Completed | University of Rochester | Phase 2/Phase 3 | 2002-11-01 | RATIONALE: Buspirone may be effective in reducing dyspnea (shortness of breath) in patients with cancer who are undergoing chemotherapy. PURPOSE: Randomized clinical trial to study the effectiveness of buspirone in reducing shortness of breath in patients who are undergoing chemotherapy for cancer. |
| NCT00086112 ↗ | Study Comparing Risperidone vs Placebo as add-on Therapy in Patients With Generalized Anxiety Disorder Who Are Sub-optimally Responding to Standard Therapy. | Completed | Janssen, LP | Phase 3 | 1969-12-31 | The purpose of this trial is to determine the effectiveness of risperidone as an adjunctive treatment in patients with GAD who demonstrate a less-than-optimal response to their current anxiolytic treatment. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Buspirone Hydrochloride
Condition Name
Clinical Trial Locations for Buspirone Hydrochloride
Trials by Country
Clinical Trial Progress for Buspirone Hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for Buspirone Hydrochloride
Sponsor Name
